I can extract side effects

The major domestic pharmaceutical companies were all stunned when they saw the price of Sanqing's anti-cancer drug included in the medical insurance.

Raging anger gushed out from the hearts of the CEOs of pharmaceutical companies.

"Is this Wei Kang an idiot? How dare he set such a low price?"

"This is to drive us to death."

"He wants to monopolize the anti-cancer drug market. It's a wolf's ambition. He's not a son of man!"

"It's so black-hearted, I actually believe that he will cooperate with us to develop the anti-cancer drug market together."

Impotent rage was followed by deep fear.

"It seems that the anticancer drug market is about to change."

"The company should transform as soon as possible."

"All anti-cancer generic drugs are given up. No matter how cheap they are, no one will buy them, let alone expensive self-developed drugs."

"We can only try our best to open up overseas markets. We want to sell anticancer drugs abroad."

"Pfizer is currently selling Sanqing anti-cancer drugs in Europa and Eagle Country, but in the vast third world countries, the market there is still blank, and we still have a lot of room for development."

"If you can't provoke it, you can always hide it. Sanqing now has an anti-cancer drug, and our company has many types of drugs. We are going to invest all our resources in other fields and completely give up the anti-cancer drug market."

"That's it. I don't believe that Sanqing can launch other new drugs so quickly."

The CEOs of pharmaceutical companies are busy communicating with familiar colleagues, and then change their strategic layout, withdraw from the anti-cancer drug market one after another, invest all resources in other drug fields, and go all out to seize overseas markets.

Among them, Xinmei Group suffered the most severe blow. The Akilunsa injection they had just developed was attacked by competitors as soon as it was launched.

Chairman Wu Shiji sat in the high-level office on the Bund, watching the stock price plummeting, almost crying.

The investment of 800 million yuan in new drugs has been in vain like this, and no bubbles have been seen. How can we face the shareholders' questions?

I think that at the beginning, I entered the anti-cancer drug track with high spirits, invested huge sums of money in the research and development of new domestic drugs, and finally achieved results. I encountered a monster like Sanqing, who not only developed a broad-spectrum anti-cancer drug, but also broke the price.

This simply makes all domestic anticancer drugs dead, and the price cannot recover the cost at all.

Because almost all targeted drugs and immune drugs are only aimed at patients with a certain type of cancer. If it is a small cancer, there are not many patients. up.

The more cancers that can be treated, the bigger the market for this anti-cancer drug, which is why Sanqing's broad-spectrum anti-cancer drug swept the market as soon as it was born.

Mr. Wu was in a daze, feeling that he was about to face the storm of the board of directors. After thinking about it, he suddenly picked up the phone and dialed a familiar number.

"Old grandson, long time no see, how are you doing?"

"Hehe, Mr. Wu, why did you call me when you are so busy? What's the matter?"

Mr. Wu looked a little embarrassed, and quickly squeezed out a smile and said: "Old Sun, you see, we have known each other for so many years. Before I founded Xinmei, the old Mr. Wei of Sanqing was still my old leader. We all It's a colleague in the same department, you see, no one can compare to this friendship."

Sun Chengren on the opposite side hurriedly interrupted him: "Stop, stop! If you have something to say, talk it out, and don't talk about it. There is not much left of our friendship after so many years. What did you do back then? I know it."

Mr. Wu said with a bitter face: "Oh, I didn't kill them all back then, I always left room for my love back then, otherwise you think if I were really ruthless, Sanqing would still be able to survive until now? "

Sun Chengren was silent, perhaps recalling some past events, he sighed after a long time and said, "Let's talk about something, I'm a bit nostalgic at this age."

Mr. Wu raised his brows with joy, and hurriedly said: "Our company's new anti-cancer drugs are probably losing money, so I want to inquire about the direction of Sanqing's new drug research and development, and see if we can avoid you. After so many years of competition, we have won the old man. Mr. Wei finally fell into the hands of Mr. Wei, and as expected, the waves behind the Yangtze River push the waves ahead, I am convinced."

Sun Chengren pondered for a moment and said, "I'm not in charge of research and development, and I can't help you with this. If there is any news, I will try my best to inform you as soon as possible, so that you Xinmei don't have to waste your efforts in vain."

As he was talking, he suddenly couldn't help laughing wildly: "Haha, Mr. Wu of the dignified 100-billion listed company is also asking me to get a relationship and go through the back door? It makes me laugh to death. I didn't even dare to think about this scene a few years ago. , damn it, it's so fucking comfortable."

Mr. Wu kept his expression on his face and his heart skipped a beat, and said with a playful smile, "Isn't this a friendship with Mr. Sun? I can't get ahead of Mr. Wei. He is a person who has dealings with academician Qi and the president of Pfizer."

Sun Chengren agreed: "That's right, Mr. Wei can't reach anyone now, and you, Mr. Wu, are on the same level as me."

Mr. Wu's face couldn't stop beating, but he continued to make friends with a smile: "Haha, you are too polite. It is my honor to be on the same level as Mr. Sun. It seems that Brother Sun still remembers the friendship with me back then. Are you free for two days? Have a meal together and meet old friends?"

Mr. Wu and Sun Chengren made an appointment to get together, and finally hung up the phone.

The smile on his face quickly disappeared, and his expression became gloomy.

After a while, he quickly called his assistant.

"Xiao Zhou, prepare materials for me and make a plan for entering the Chinese patent medicine market. The sooner the better, I will use it on the board of directors."

He has already made up his mind. Judging from the several drugs developed by Sanqing, Weikang is very strong in Western medicine. The research and development strength is too strong, which makes people despair. How to focus on aggressive expansion and seize the market.

The Chinese patent medicine market is a very good direction. Sanqing has not made any achievements in this field and has not shown any interest in it. This is very suitable for Xinmei to flex its muscles.

At the same time, in order to recover the investment loss of Aquilunsa injection, he also decided to explore overseas markets as soon as possible.

The two directions of overseas markets and Chinese patent medicines, two-pronged approach, must be able to create a new world.

Thinking of this, Mr. Wu smiled complacently, and the haze in his heart was swept away.

*****

Eagle Country, Pfizer headquarters.

An extremely spacious large conference room was filled with senior executives of Pfizer's board of directors.

A huge screen on the wall shows the figures of other pharmaceutical giant CEOs.

Different from the grief and indignation of domestic pharmaceutical companies, the atmosphere in the entire meeting room is quite relaxed and happy.

"Then, let's make a happy decision like this."

"Our Pfizer's anti-cancer drug has remarkable curative effect and no side effects. Such a good drug must take a high-end route."

"In the future, it will mainly be sold to high-net-worth individuals, the world's rich and high-salary middle class. They are our favorite high-end customers. They are rich and generous, and they are very willing to see a doctor and take medicine."

"As for Merck, Roche, and other companies, you can lower the price, so that you can grab other customer groups. After all, Ke Ruida has been selling for so many years, and you have already earned enough."

"Of course, we will also reach an agreement with the doctor's association, so that they try their best to recommend patients to use various targeted drugs first, and wait until the patients develop drug resistance, then they will grandly launch the Sanqing anticancer drug, so that everyone's drugs can be used. If there is an opportunity, we can fully tap the value of a customer."

"You see, we at Pfizer should be very sincere."

The CEOs and chairman of the giants on the screen nodded one after another, looking very satisfied.

"Pfizer is indeed very sincere. Selling at a high price is only good for us, and there is no harm. We just need to lower the price, and it will not affect profits too much."

"That's right. Those patients at the bottom could not afford medicines before, but now they can afford anti-cancer drugs at reduced prices, and we can maintain sales. It's a win-win situation."

"That's right, we are also doing good deeds and treating those poor patients."

"High-end customers are more pursuing treatment experience. They choose Sanqing, and we have no choice. Now we can divide their respective market scopes, which is already the best result."

"Okay, now that everyone has reached a consensus, this meeting has come to a successful conclusion."

The CEO of Pfizer saw that everyone had no further comments, and ended the meeting with a smile.

He turned around and praised Andre: "Andre, you did a great job. Thanks to you getting this anticancer drug early, we can monopolize the global high-end market."

"Congratulations. From today, you have officially become the president of Pfizer's global anti-tumor department. I hope you can maintain your friendship with Sanqing and continue to cooperate."

Andre stood up amid applause and accepted the appointment.

He was very excited at the moment, his hard work was finally promoted and his salary increased, and the fruits of this harvest were extremely sweet.

After the meeting, he quickly contacted Wei Kang and told him a piece of good news.

"Dear Wei, Pfizer has passed the $2.5 billion milestone payment."